ADMA Biologics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 28, 2024 at 04:05 pm EST
Share
ADMA Biologics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 73.9 million compared to USD 49.98 million a year ago. Net loss was USD 17.64 million compared to USD 12.23 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.06 a year ago.
For the full year, the company reported sales was USD 258.22 million compared to USD 154.08 million a year ago. Net loss was USD 28.24 million compared to USD 65.9 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.33 a year ago. Diluted loss per share from continuing operations was USD 0.13 compared to USD 0.33 a year ago.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
ADMA BIOLOGICS, INC. 
